Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02349139 · ClinicalTrials.gov registry record · Phase 1
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
A Phase 1 study, sponsored by Asana BioSciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02349139 is a Phase 1 study that was terminated before completion, run by Asana BioSciences. The registered enrollment target is 27 participants.
The verdict
NCT02349139, a Phase 1 study, was terminated before completion, sponsored by Asana BioSciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study will be conducted in three parts. Part A is a dose-escalation study to determine two safe and tolerable doses of ASN001 for men with metastatic castration resistant prostate cancer. Part A will also characterize the pharmacokinetics and pharmacodynamics of the ASN001 through blood sampling. Subjects in Part B will receive one of two doses identified in Part A to determine which one is more effective, and collect additional pharmacokinetic data. Part C is an extension for subjects completing either Part A or B.
Interventions
- DRUG ASN001: Escalating dose Part A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-01-19 |
| Est. Completion | 2017-08-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02349139
The ClinicalTrials.gov registry entry for NCT02349139 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Asana BioSciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ASN001: Escalating dose Part A is the first listed.
NCT02349139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02349139 about?
NCT02349139 is a clinical study titled "Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer". This study will be conducted in three parts. Part A is a dose-escalation study to determine two safe and tolerable doses of ASN001 for men with metastatic castration resistant prostate cancer. Part A will also characterize the pharmacokinetics and pharmacodynamics of the ASN001 through blood samplin...
What is the current status of trial NCT02349139?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2015-01-19. Estimated completion is 2017-08-17.
What interventions are being tested in trial NCT02349139?
The interventions under investigation include: ASN001: Escalating dose Part A (DRUG).
Who is sponsoring clinical trial NCT02349139?
This trial is sponsored by Asana BioSciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.